One of the primary challenges associated with the GRAS designation is the reliance on industry self-regulation. Although companies are required to perform rigorous testing, there is concern about potential conflict of interest. Another challenge is the evolving nature of scientific understanding. Substances once considered safe may later be reevaluated as new research emerges. Moreover, there is ongoing debate about the transparency of the GRAS notification process, as some data are considered confidential.
